Live data · NADAC + Part D CY24 · reviewed daily

Omadacycline (NUZYRA)

Tetracycline-class Antibacterial class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2019-02-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$181.7M in CY2024 Part D spend17K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
19 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Omadacycline used for?

Omadacycline is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Omadacycline?

No. Omadacycline is brand-only with no generic equivalents currently in market.

How much does my plan pay for Omadacycline?

NADAC pricing data not currently available for this drug.

Is Omadacycline on the FDA shortage list?

No. Omadacycline is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.